tetano
Editor, Senior Moderator
Viruses
. 2023 Mar 22;15(3):811.
doi: 10.3390/v15030811.
Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting
Yoshikazu Mutoh[SUP] 1 [/SUP], Takumi Umemura[SUP] 2 [/SUP], Takeshi Nishikawa[SUP] 1 [/SUP], Kaho Kondo[SUP] 3 [/SUP], Yuta Nishina[SUP] 3 [/SUP], Kazuaki Soejima[SUP] 3 [/SUP], Yoichiro Noguchi[SUP] 3 [/SUP], Tomohiro Bando[SUP] 3 [/SUP], Sho Ota[SUP] 3 [/SUP], Tatsuki Shimahara[SUP] 3 [/SUP], Shuko Hirota[SUP] 3 [/SUP], Satoshi Hagimoto[SUP] 3 [/SUP], Reoto Takei[SUP] 3 [/SUP], Jun Fukihara[SUP] 3 [/SUP], Hajime Sasano[SUP] 3 [/SUP], Yasuhiko Yamano[SUP] 3 [/SUP], Toshiki Yokoyama[SUP] 3 [/SUP], Kensuke Kataoka[SUP] 3 [/SUP], Toshiaki Matsuda[SUP] 3 [/SUP], Tomoki Kimura[SUP] 3 [/SUP], Toshihiko Ichihara[SUP] 1 2 [/SUP], Yasuhiro Kondoh[SUP] 3 [/SUP]
Affiliations
Abstract
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for patients with the 2019 coronavirus (COVID-19). However, little is known about their effectiveness in older adults and those at high risk of disease progression. This retrospective single-center observational study assessed and compared the outcomes of COVID-19 treated with MOV and NMV/r in a real-world community setting. We included patients with confirmed COVID-19 combined with one or more risk factors for disease progression from June to October 2022. Of 283 patients, 79.9% received MOV and 20.1% NMV/r. The mean patient age was 71.7 years, 56.5% were men, and 71.7% had received ≥3 doses of vaccine. COVID-19-related hospitalization (2.8% and 3.5%, respectively; p = 0.978) or death (0.4% and 3.5%, respectively; p = 0.104) did not differ significantly between the MOV and NMV/r groups. The incidence of adverse events was 2.7% and 5.3%, and the incidence of treatment discontinuation was 2.7% and 5.3% in the MOV and NMV/r groups, respectively. The real-world effectiveness of MOV and NMV/r was similar among older adults and those at high risk of disease progression. The incidence of hospitalization or death was low.
Keywords: COVID-19; adverse event; hospitalization; molnupiravir; nirmatrelvir/ritonavir; older adults.
. 2023 Mar 22;15(3):811.
doi: 10.3390/v15030811.
Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting
Yoshikazu Mutoh[SUP] 1 [/SUP], Takumi Umemura[SUP] 2 [/SUP], Takeshi Nishikawa[SUP] 1 [/SUP], Kaho Kondo[SUP] 3 [/SUP], Yuta Nishina[SUP] 3 [/SUP], Kazuaki Soejima[SUP] 3 [/SUP], Yoichiro Noguchi[SUP] 3 [/SUP], Tomohiro Bando[SUP] 3 [/SUP], Sho Ota[SUP] 3 [/SUP], Tatsuki Shimahara[SUP] 3 [/SUP], Shuko Hirota[SUP] 3 [/SUP], Satoshi Hagimoto[SUP] 3 [/SUP], Reoto Takei[SUP] 3 [/SUP], Jun Fukihara[SUP] 3 [/SUP], Hajime Sasano[SUP] 3 [/SUP], Yasuhiko Yamano[SUP] 3 [/SUP], Toshiki Yokoyama[SUP] 3 [/SUP], Kensuke Kataoka[SUP] 3 [/SUP], Toshiaki Matsuda[SUP] 3 [/SUP], Tomoki Kimura[SUP] 3 [/SUP], Toshihiko Ichihara[SUP] 1 2 [/SUP], Yasuhiro Kondoh[SUP] 3 [/SUP]
Affiliations
- PMID: 36992519
- DOI: 10.3390/v15030811
Abstract
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for patients with the 2019 coronavirus (COVID-19). However, little is known about their effectiveness in older adults and those at high risk of disease progression. This retrospective single-center observational study assessed and compared the outcomes of COVID-19 treated with MOV and NMV/r in a real-world community setting. We included patients with confirmed COVID-19 combined with one or more risk factors for disease progression from June to October 2022. Of 283 patients, 79.9% received MOV and 20.1% NMV/r. The mean patient age was 71.7 years, 56.5% were men, and 71.7% had received ≥3 doses of vaccine. COVID-19-related hospitalization (2.8% and 3.5%, respectively; p = 0.978) or death (0.4% and 3.5%, respectively; p = 0.104) did not differ significantly between the MOV and NMV/r groups. The incidence of adverse events was 2.7% and 5.3%, and the incidence of treatment discontinuation was 2.7% and 5.3% in the MOV and NMV/r groups, respectively. The real-world effectiveness of MOV and NMV/r was similar among older adults and those at high risk of disease progression. The incidence of hospitalization or death was low.
Keywords: COVID-19; adverse event; hospitalization; molnupiravir; nirmatrelvir/ritonavir; older adults.